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Abstract
Background
CD8+ T-cells are located in the small airways of COPD patients and may contribute to
pathophysiology. CD8+ cells express the chemokine receptor, CXCR3 that binds CXCL9,
CXCL10 and CXCL11, which are elevated in the airways of COPD patients. These chemo-
kines are released from airway epithelial cells via activation of receptor associated Janus
kinases (JAK). This study compared the efficacy of two structurally dissimilar pan-JAK in-
hibitors, PF956980 and PF1367550, and the glucocorticosteroid dexamethasone, in BEAS-
2B and human primary airway epithelial cells from COPD patients and control subjects.
Methods
Cells were stimulated with either IFNγ alone or with TNFα, and release of CXCL9, CXCL10
and CXCL11 measured by ELISA and expression of CXCL9, CXCL10 and CXCL11 by
qPCR. Activation of JAK signalling was assessed by STAT1 phosphorylation and DNA
binding.
Results
There were no differences in the levels of release of CXCL9, CXCL10 and CXCL11 from
primary airway epithelial cells from any of the subjects or following stimulation with either
IFNγ alone or with TNFα. Dexamethasone did not inhibit CXCR3 chemokine release from
stimulated BEAS-2B or primary airway epithelial cells. However, both JAK inhibitors sup-
pressed this response with PF1367550 being ~50-65-fold more potent than PF956980.
The response of cells from COPD patients did not differ from controls with similar responses
regardless of whether inhibitors were added prophylactically or concomitant with stimuli.
These effects were mediated by JAK inhibition as both compounds suppressed STAT1
phosphorylation and DNA-binding of STAT1 and gene transcription.
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Conclusions
These data suggest that the novel JAK inhibitor, PF1367550, is more potent than
PF956980 and that JAK pathway inhibition in airway epithelium could provide an alternative
anti-inflammatory approach for glucocorticosteroid-resistant diseases including COPD.
Introduction
Type-1 helper (Th1) lymphocytes and CD8+ T cells are elevated in a number of inflammatory
diseases including chronic obstructive pulmonary disease (COPD) [1] where these cells are lo-
cated at the sites of airways obstruction [2, 3] and may contribute to emphysema via the pro-
duction of granzyme B and perforins [4]. Recently, these cells have been shown to exhibit
reduced apoptosis in COPD patients [5] leading to the persistence of these inflammatory cells
in the airways. COPD is currently the fifth leading cause of death globally [6] and is increasing
in prevalence with estimates that it affects ~10% of the population over the age of 40 [7]. Al-
though inflammation underpins the pathophysiology of COPD, current anti-inflammatory
treatments, including glucocorticosteroids, are ineffective [8]. Therefore, alternative strategies
are required, for example, reducing recruitment of CD8+ cells to the airways of patients with
COPD might prove to be beneficial.
The chemokine receptor, CXCR3 is highly expressed by activated Th1 and CD8+ lympho-
cytes and is thought to be involved in recruitment of these cells to the sites of inflammation [9].
CXCR3 binds to three distinct ELR negative ligands, CXCL9 (monokine induced by interferon
γ (IFNγ); MIG), CXCL10 (interferon inducible protein of 10 kDa; IP10) and CXCL11 (interfer-
on inducible T-cell α chemoattractant; ITAC) [10], all of which are elevated in the airways of
patients with COPD [11] with CXCL10 being elevated in both sputum and serum during a
viral exacerbation [12, 13] Although all three of these chemokines bind to the CXCR3 receptor,
however CXCL11 has increased affinity and CXCL9 the least, implying a hierarchy of activity
[9]. The source of these chemokines in the airways of COPD is unclear, however bronchial air-
way epithelial cells [14–16] and airway smooth muscle cells [17] release these chemokines fol-
lowing stimulation with interferon (IFN)-γ in both the presence and absence of tumour
necrosis factor (TNF)α. Classically, binding of IFNγ activates Janus kinases (JAK) 1 and 2 lead-
ing to phosphorylation of signal transducer and activation of transcription (STAT)-1 protein,
which subsequently dimerizes and binds to genes containing γ-activated sequences [18] includ-
ing CXCL9, CXCL10 and CXCL11. STAT-1 independent mechanisms may also be invoked
and STAT-3 and STAT-5 have been reported to be activated through the IFNγ receptor [19,
20]. Release of CXCL9, CXCL10 and CXCL11 from both airway epithelial cells and airway
smooth muscles can be potentiated by the synergistic interactions of TNFα with IFNγ [14, 21].
In the airways of COPD patients, the concentrations of TNFα are elevated [22] and thus the ex-
pression of CXCL9, CXCL10 and CXCL11 by structural cells of the airways is likely to be en-
hanced, driving lymphocyte recruitment.
Previously, we have shown that the epithelial cell line BEAS-2B releases CXCL9, CXCL10
and CXCL11 in response to IFNγ in a manner that is glucocorticosteroid-insensitive but re-
sponsive to inhibition via the IκB kinase, IKK2 [15]. The present study utilized our previous
model to assess whether direct inhibition of the JAK pathway could suppress release of CXCL9,
CXCL10 and CXCL11 from human lung epithelial cells using two structurally dissimilar
compounds. PF956980 ([23]-pyrrolidin-1-yl-methanone hydrate) is a pan-JAK inhibitor with
little effect against other kinases, including IKK [24] whereas the novel compound, PF1367550
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(4-(3-(1H-benzo[d]imidazol-2-yl)-1H-indazol-6-yl)-3-ethylphenol), is a structurally differen-
tiated, indazole pan-JAK inhibitor with excellent selectivity over non-JAK kinases [25]. Both of
these JAK inhibitors were assessed for efficacy and potency to suppress CXCR3 chemokine re-
lease from both BEAS-2B cells and human primary airway epithelial cells with a view to under-
standing the utility of JAK inhibitors as therapeutic agents for inflammation in diseases such as
COPD.
Materials and Methods
Materials
All chemicals and reagents were from Sigma Chemical Co (Poole, Dorset, UK) unless indicated
otherwise. PF956980 and PF1367550 were kind gifts from Pfizer Inc. (Cambridge, Mass). All
drugs were reconstituted at a concentration of 10mM in DMSO and diluted from these stock
solutions for use in experiments. All experiments were performed with an appropriate vehicle
control which had no effect on any of the responses measured.
Cell culture
BEAS-2B cells (catalogue number CRL-9609) were purchased directly from American Type
Culture Collection (Rockville, MD). Keratinocyte serum-free medium (K-SFM), bovine pitui-
tary extract (BPE), and recombinant human epidermal growth factor (EGF) were purchased
from Invitrogen (Paisley, UK). BEAS-2B cells were cultured in K-SFM containing 50 μg/ml
BPE and 5 ng/ml EGF at 37°C in a humidified atmosphere comprising 5% (v/v) CO2 in air.
Cells were cultured as monolayers in growth factor-free media for 24 h prior to stimulation.
Human primary airway epithelial cells were cultured as monolayers from bronchial brushings
from both male and female subjects (Table 1) and cultured in LHC-9 media (Invitrogen, Pais-
ley, UK) in collagen (1% w/v) coated flasks. Samples were obtained from non-smokers, smok-
ers and patients with COPD. Smokers had a smoking history of at least 10 pack-years and
COPD patients were stable and fulfilled the American Thoracic Society criteria [26]. The sub-
jects were matched for age and smokers and COPD patients for smoking history (Table 1). All
subjects gave informed written consent and the study was approved by the NRES London-
Chelsea Research Ethics committee, study number 09/H0801/85.
Table 1. Demographic data for subjects providing primary human airway epithelial cells.
Non-smokersn = 4 Smokersn = 5 COPDn = 7
Age (years) 61 ± 10 53 ± 10 66 ± 4
Gender M:F 2:2 2:3 2:6
FEV1(L) 2.2 ± 0.4 2.3 ± 0.3 0.8± 0.2**
##
FVC (L) 2.8 ± 0.6 2.9 ± 0.3 1.8 ± 0.2*
FEV1 (% predicted) 79 ± 2 89 ± 8 38 ± 10**
FVC (% predicted) 83 ± 1 93± 8 65 ± 9
FEV1:FVC 0.83 ± 0.03 0.76 ± 0.05 0.44 ± 0.09*
#
Smoking History (Pack Years) - 23 ± 5 38 ± 6
Data are presented as mean ± S.E.M.
*p<0.05 and
**p<0.01 vs smokers
#p<0.05 and
##p<0.01 vs non-smokers.
doi:10.1371/journal.pone.0128757.t001
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Measurement of CXCL9, CXCL10 and CXCL11
Cell-free supernatants were removed 20h post-stimulation and assayed for CXCL9, CXCL10
and CXCL11 using Duoset ELISA kits (R & D Systems Europe, Abingdon, UK) according to
the manufacturer’s instructions. The detection limits of these assays are 62pg/ml, 31pg/ml, and
7.8 pg/ml respectively.
Cell viability
Cell viability was determined colorimetrically by measuring the reduction of 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, MTT, to formazan by mitochon-
drial dehydrogenases, as described previously [27].
Western Blotting
Enhanced chemiluminescence (ECL) reagent and Hybond-ECL nitrocellulose were obtained
from GE Healthcare (Little Chalfont, UK). Bis-Tris SDS-PAGE (4–12%) gels and buffers were
purchased from Invitrogen Ltd (Paisley, Scotland, UK). Antibodies against phosphorylated
and total STAT-1 were purchased from New England Biolabs (Hitchin, UK). Epithelial cells
were treated as indicated in six-well plates and lysed in 10 mM Tris-HCl buffer (pH 7.5) con-
taining 150 mMNaCl, 2 mM EDTA, 1 mM sodium orthovanadate, 1% (v/v) Triton X-100, 1
mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, and 10 μg/ml aprotinin) for 30 min on
ice. The lysates were then centrifuged at 12,000g for 15 min and protein concentration deter-
mined using the BCA protein assay (BioRad, Hemel Hempstead, UK). The proteins within the
lysates (20 μg) were resolved with 4–12% Bis-Tris gels and transferred onto nitrocellulose
membranes. The membranes were then blocked with 5% (w/v) non-fat milk in TBS containing
0.1% (v/v) Tween 20 for 1 h at room temperature and then incubated with antibodies specific
for pSTAT-1 overnight at 4°C. The primary antibody was detected with peroxidase-conjugated
secondary antibodies and labelled proteins were detected by ECL.
STAT Activation Assays (TransAM)
STAT phosphorylation, nuclear translocation and DNA binding was determined using
TransAM assays (Actif Motif, Rixensart, Belgium). Cells were treated with JAK inhibitors for
30 min prior to stimulation for 1h. Nuclear extracts were prepared using the Actif Motif assay
reagents. Briefly, the nuclear extracts (10 μg) were incubated in DNA coated plates for 1h.
After washing, antibodies supplied with the TransAM kit that were specific for the active forms
of STAT1, STAT3, STAT5A and STAT5B were added to the wells and incubated for a further
hour. The plates were washed and a secondary HRP-labelled anti-goat Ig antibody was added
and the plates incubated for an hour. After washing, the assay was developed using the TMB
substrate provided and the reaction stopped using 2N sulphuric acid. The plates were read at
450nm with a reference filter of 610nm. Data were then normalised to non-stimulated cells
and calculated as fold change from baseline.
Measurement of mRNA Expression of CXCL9, CXCL10 and CXCL11
Total RNA was extracted from cells and reverse transcribed, as described previously [15]. Gene
expression was determined by Taqman real-time PCR on a 7500 Real Time PCR system (Ap-
plied Biosystems, Life Technologies Ltd, Paisley, UK) using PCRMaster Mix Reagent and ‘as-
says on demand’ (Applied Biosystems). HPRT1 gene expression was used as the housekeeping
gene and data presented as δδCT relative to baseline.
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Statistical Analyses
Data are presented as mean ± SEM of ‘n’ independent determinations. Concentration-response
curves were analysed by least-squares, non-linear iterative regression with the ‘Graphpad
Prism’ curve fitting program (GraphPad software, San Diego, USA) and IC50 values were sub-
sequently interpolated from curves of best-fit. Statistical differences were determined using the
Kruskal–Wallis test followed by Dunn's multiple comparison test or a Wilcoxon signed rank
test as appropriate. Values of P<0.05 were considered significant.
Results
CXCR3 chemokine release from epithelial cells
Initial experiments were devised to compare the release of CXCL9, CXCL10 and CXCL11 from
BEAS-2B cells and primary human airway epithelial cells. IFNγ (10ng/ml) in both the absence
and presence of TNFα stimulated the release of CXCL9, CXCL10 and CXCL11 from both cell
types (Fig 1). IFNγ and TNFα operated synergistically to stimulate release of CXCL9, CXCL10
and CXCL11 from BEAS-2B cells and (Fig 1) primary human airway epithelial cells with no
differences in responses of the two cell types (Fig 1). There were no differences in the responses
of human primary airway epithelial cells derived from non-smokers, smokers or patients with
COPD with respect to any of the stimuli examined (Fig 1B, 1D and 1F) These data suggest that
BEAS-2B cells are a good model for the release of CXCL9, CXCL10 and CXCL11 from human
airway epithelia and that human primary airway epithelial cells from COPD patients do not re-
lease greater levels of CXCL9, CXCL10 and CXCL11 than cells obtained from control subjects.
Effect of JAK inhibitors on CXCR3 chemokine release
The effect of two, distinct JAK inhibitors on the release of CXCL9, CXCL10 and CXCL11 was
investigated using both BEAS-2B cells and primary airway epithelial cells and compared to the
effect of a glucocorticosteroid, dexamethasone. The selectivity of PF956980 has been reported
previously [24] with a reported IC50 of 22nM for JAK/JAK3 and 188 nM for JAK2 in a cellular
assay, whereas the selectivity of PF1367550 is reported in Table 2. PF956980 has been reported
to be inactive or with an IC50>30μM against AKT, AuroraA, cdk2, cdk6,CHK1, FGFR1,
GSK3b, IKKb, IKKi, INSR, MAPK1, MAPKAP-K2, MASK,MET, PAK4, PDK1, PKCb,
ROCK1, TaoK3, TrkA [24]. Both JAK inhibitors, PF956980 and PF1367550, attenuated IFNγ-
stimulated and IFNγ+TNFα-stimulated CXCR3 chemokine release from BEAS-2B cells in a
concentration-dependent manner (Fig 2) (Table 3), with PF1367550 being ~50-fold more po-
tent than PF956980. This contrasts with dexamethasone, which had a very limited effect on
CXCL9 and CXCL11 release (Fig 2A, 2C, 2D and 2F) but a maximal ~50% inhibitory effect on
IFNγ-stimulated release of CXCL10 (Fig 2B) but none when CXCL10 was measured following
stimulation with IFNγ and TNFα together (Fig 2E).
It was possible that concomitant addition of stimulus and JAK inhibitors may elicit a differ-
ent inhibitory profile, therefore to address this, experiments were performed. Addition of both
cytokines concomitantly with PF956980 or PF1367550 showed similar inhibitory profiles to
those exhibited when inhibitors were added prophylactically (S1 Fig) with no difference in IC50
values (S1 Table). Experiments were then performed to determine the effects of both JAK in-
hibitors in human primary airway epithelial cells in order to determine whether their ability to
suppress CXCR3 chemokine release from BEAS-2B cells was reflective of their efficacy in pri-
mary cells. Again, both PF956980 and PF1367550, inhibited both IFNγ-stimulated and IFNγ
+ TNFα-stimulated CXCR3 chemokine release from human primary airway epithelial cells in a
concentration-dependent manner irrespective of the source of the primary airway epithelial
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cells (S2–S4 Figs, Table 4) with cells from non-smokers, smokers and COPD patients respond-
ing similarly. Therefore, the data from all primary cells were pooled to increase statistical
power (Fig 3) (Table 5) and showed that PF1367550 was ~80-fold more potent than PF956980.
In these experimental systems, dexamethasone did not suppress CXCR3 chemokine release.
In order to determine whether any of the inhibitory effects of the JAK inhibitors could be at-
tributed to cell death, MTT assays were performed at the end of every experiment. PF956980
had no effect on cell viability at any of the concentrations used in this study. PF1367550 had
no effect on cell viability within 103 of the IC50 for this compound and therefore any observed
inhibitory effects are driven the pharmacological mechanism, since at 10-6M, and at all concen-
trations below this, both inhibitors showed no alterations in cell viability compared to untreat-
ed cells. Therefore, the effect of the JAK inhibitors to suppress CXCR3 chemokine release is
not related to cell toxicity. The limited effect of dexamethasone in these systems suggested that
the cells used in this study may be glucocorticosteroid-insensitive. In order to address this
issue, the levels of IL-6 released from cells stimulated with IFNγ + TNFα were measured. At
baseline, BEAS-2B cells and human primary airway epithelial cells release 41±15 pg/ml, n = 8
and 236±86 pg/ml, n = 7, IL-6 respectively. These levels are increased in the presence of IFNγ +
TNFα to 1480±142 pg/ml, n = 4 and 1077±267 pg/ml, n = 7 for BEAS-2B cells and primary air-
way epithelial cells, respectively. In the presence of dexamethasone, IL-6 release was suppressed
Fig 1. Effect of IFNγ in the presence and absence of TNFα on the release of CXCL9, CXCL10 and CXCL11 from BEAS-2B and primary human
airway epithelial cells. BEAS-2B cells, n = 11 (open bars, panels a, c and e) or human primary airway epithelial cells from non-smokers (n = 4) (closed bars),
smokers (n = 5) (horizontal lines) or patients with COPD (n = 7) (hatched bars) (panels b, d and f) were incubated for 20h in the absence or presence of IFNγ
(10ng/ml) or IFNγ + TNFα (10ng/ml). Media was harvested and the concentrations of CXCL9 (panels a and b), CXCL10 (panels c and d) and CXCL11
(panels e and f) were measured by ELISA. Data are presented as mean ± SEM, where * represents p<0.05, **p<0.01 and ***p<0.001.
doi:10.1371/journal.pone.0128757.g001
Table 2. Selectivity of PF1367550.
Kinase IC50
JAK1 Km 0.8 nM
JAK1 1 mM 0.4 nM
JAK2 Km 1.0 nM
JAK2 1 mM 1.3 nM
JAK3 Km 1.0 nM
JAK3 1 mM 14 nM
TYK2 Km 0.8 nM
TYK2 1 mM 8.4 nM
IL-2-induced P-STAT5 human T lymphocytes (JAK1/3) 11 nM
IL-2-induced IFNγ release by human T lymphocytes (JAK1/3) 14 nM
IL-12-induced IFNγ release by human T lymphocytes (JAK1/2) 45 nM
MLK1 Km 54 nM
MAP4K4 Km 60 nM
TrkA Km 227 nM
GSK3β Km 617 nM
Protein kinase C β2 Km 665 nM
MST4 Km 692 nM
TAOK2 Km 781 nM
Calculated IC50 values for PF1367550 against >50 kinases. Data are presented for the kinases that
showed >50% inhibition at 1mM ATP or at the Km as indicated (Data from Coe et al., [25]).
doi:10.1371/journal.pone.0128757.t002
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Fig 2. Effect of JAK inhibitors, PF956980 and PF1367550 and dexamethasone on IFNγ and IFNγ + TNFα-stimulated release of CXCL9, CXCL10 and
CXCL11 from BEAS-2B cells. BEAS-2B cells were pre-treated and incubated for 1h with either PF956980 (), PF1367550 (●), or dexamethasone (▲)
followed by stimulation for 20h with IFNγ (10ng/ml) (panels a-c) or IFNγ + TNFα (10ng/ml) (panels d-f). Media was harvested and the concentrations of
CXCL9 (panels a and d), CXCL10 (panels b and e) and CXCL11 (panels c and f) were measured by ELISA. Data are presented as mean±SEM, n = 7–8.
doi:10.1371/journal.pone.0128757.g002
Table 3. IC50 values for PF956980 and PF1367550 on IFNγ and IFNγ+TNFα-stimulated release of CXCL9, CXCL10 and CXCL11 from BEAS-2B cells.
PF956980 IC50 (μM) PF1367550 IC50 (nM)
Chemokine IFNγ IFNγ+TNFα IFNγ IFNγ+TNFα
CXCL9 0.4 ± 0.1 0.6 ± 0.1 3.6 ± 1.4 13.3 ± 2.0
CXCL10 0.6 ± 0.3 2.2 ± 0.3 6.1 ± 2.0 50.3 ± 8.5
CXCL11 0.5 ± 0.1 0.9 ± 0. 3 11.5 ± 2.0 13.9 ± 2.6
BEAS-2B cells were pre-treated for 1h in the presence of either PF956980 or PF1367550 prior to stimulation for 20h in the absence or presence of IFNγ
(10ng/ml) or IFNγ+TNFα (10ng/ml). After this time, media was harvested and the concentrations of CXCL9, CXCL10 and CXCL11 measured by ELISA.
Data are presented as mean±SEM, n = 7–8.
doi:10.1371/journal.pone.0128757.t003
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by ~50–70% with IC50 values of 16±8 nM and 11±7 nM respectively. Therefore, these cells are
sensitive to glucocorticosteroid inhibition; however, the release of CXCL9, CXCL10 and
CXCL11 following stimulation with either IFNγ or IFNγ in combination with TNFα is not.
Both JAK inhibitors also suppressed this response in primary airway epithelial cells but with
IC50 values of ~5 and 50-fold greater than those for inhibition of CXCR3 chemokine release
(PF956980: 11.4 ± 9 μM and PF1367550: 0.8 ± 0.2 μM, n = 7) suggesting that these effects may
be unrelated to JAK inhibition directly.
Effects of JAK inhibitors on STAT-1
Having ascertained that JAK inhibitors could suppress the glucocorticosteroid-insensitive re-
lease of CXCL9, CXCL10 and CXCL11 from airway epithelial cells, it was important to confirm
that this was via inhibition of the JAK-STAT pathway and not an off-target effect of these
agents. Activation of the JAK-STAT pathway by IFNγ leads to the phosphorylation of STAT-1,
therefore experiments were devised to assess whether PF956980 and PF1367550 altered STAT-
1 phosphorylation. BEAS-2B cells were stimulated with either IFNγ or IFNγ in combination
with TNFα and the phosphorylation of STAT-1 was measured by western blotting as reported
previously [15] (Fig 4). Exposure of cells to either IFNγ or IFNγ + TNFα increase STAT-1
phosphorylation and this was inhibited by pre-treatment with either PF956980 or PF1367550
(Fig 4) (IC50 values: PF956980; 0.94±0.16μM, and 0.84±0.21μM, n = 4 for IFNγ and IFNγ
+ TNFα stimulation respectively; PF1367550; 24±6nM, and 32±13nM, n = 4 for IFNγ and
IFNγ + TNFα stimulation respectively) with, PF1367550 being ~40-fold more potent at sup-
pressing STAT-1 phosphorylation when compared with PF956980 (Fig 4). These data in
BEAS-2B cells were further validated using human primary airway epithelial cells. Both
PF956980 and PF1367550 suppressed phosphorylation of STAT-1 by IFNγ and IFNγ + TNFα
(Fig 5). The capacity of PF956980 and PF1367550 to suppress JAK-STAT activation was fur-
ther supported by the observation that both IFNγ and IFNγ + TNFα stimulation of STAT-1
DNA binding could be suppressed by these inhibitors in BEAS-2B cells (Fig 6A). Although,
IFNγ failed to promote STAT-3 DNA binding (Fig 6B), IFNγ + TNFα significantly increased
STAT-3 binding to DNA in a manner that was suppressed by both PF956980 and PF1367550
(10-6M). There was no activation of STAT-5A or STAT-5B in this system (data not shown).
Table 4. IC50 values for PF956980 and PF1367550 on IFNγ and IFNγ+TNFα-stimulated release of CXCL9, CXCL10 and CXCL11 from human primary
airway epithelial cells from non-smokers, smokers and COPD patients.
PF956980 EC50 (μM) PF1367550 EC50 (nM)
IFNγ CXCL9 CXCL10 CXCL11 CXCL9 CXCL10 CXCL11
Non-smokers 0.88 ± 0.39 n = 4 0.81 ± 0.15 n = 4 0.66 ± 0.24 n = 4 9.73 ± 3.5 n = 3 12.8 ± 5.6 n = 3 8.5 ± 0.7 n = 3
Smokers 0.55 ± 0.09 n = 4 1.28± 0.36 n = 4 0.78 ± 0.16 n = 4 9.0 ± 3.00 n = 4 12.3± 0.36 n = 4 6.8 ± 1.9 n = 4
COPD 0.63 ± 0.09 n = 5 0.53 ± 0.01 n = 5 0.82 ± 0.25 n = 5 7.4 ± 1.3 n = 6 7.1 ± 1.3 n = 6 6.3 ± 1.4 n = 6
IFNγ +TNFα
Non-smokers 0.61 ± 0.26 n = 4 2.72 ± 0.36 n = 4 1.85 ± 0.67 n = 4 14.1 ± 7.1 n = 3 20.3 ± 5.1 n = 3 13.7 ± 6.7 n = 3
Smokers 0.35 ± 0.26 n = 4 1.88 ± 0.41 n = 4 0.87 ± 0.13 n = 4 15.3 ± 4.8 n = 4 20.2 ± 3.6 n = 4 11.8 ± 2.9 n = 4
COPD 0.59± 0.38 n = 5 1.84 ± 0.40 n = 5 1.92 ± 0.67 n = 5 20.8 ± 4.8 n = 6 29.1± 3.5 n = 6 16.7 ± 4.1 n = 6
Human primary airway epithelial cells were pre-treated for 1h in the presence of either PF956980 or PF1367550 prior to stimulation for 20h in the absence
or presence of IFNγ (10 ng/ml) or IFNγ+TNFα (10 ng/ml). After this time, media was harvested and the concentrations of CXCL9, CXCL10 and CXCL11
measured by ELISA. Data are presented as mean±SEM.
doi:10.1371/journal.pone.0128757.t004
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Effects of JAK inhibitors on CXCL9, CXCL10, CXCL11 gene transcription
In order to demonstrate that suppression of STAT-1 activation leads to reduced gene expres-
sion, experiments were performed using BEAS-2b cells that had been pretreated with JAK in-
hibitors for 1h prior to stimulation with either IFNγ or IFNγ with TNFα for 4h and RNA
isolated (Fig 7). PF956980 suppressed expression of CXCL9, CXCL10 and CXCL11 in a concen-
tration dependent manner irrespective of stimuli (Fig 7). In contrast, PF1367550 completely in-
hibited expression of all three genes at all concentrations used. Taken together these data
suggest that JAK inhibition suppresses release of CXCL9, CXCL10 and CXCL11 by reducing
gene transcription which contrasts with the effect of dexamethasone, which had no effect on
gene transcription in this system.
Fig 3. Effect of JAK inhibitors, PF956980 and PF1367550 and dexamethasone on IFNγ and IFNγ+TNFα-stimulated release of CXCL9, CXCL10 and
CXCL11 from human primary airway epithelial cells.Human primary airway epithelial cells were pre-treated for 1h with either PF956980 (), PF1367550
(●), or dexamethasone (▲) followed by stimulation for 20h with IFNγ (10 ng/ml) (panels a-c) or IFNγ + TNFα (10 ng/ml) (panels d-f). Media was harvested and
the concentrations of CXCL9 (panels a and d), CXCL10 (panels b and e) and CXCL11 (panels c and f) were measured by ELISA. Data are presented as
mean ± SEM, n = 10–13.
doi:10.1371/journal.pone.0128757.g003
JAK Inhibition of CXCR3 Chemokines
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Table 5. IC50 values for PF956980 and PF1367550 on IFNγ and IFNγ+TNFα-stimulated release of CXCR3 chemokinesCXCL9, CXCL10 and CXCL11
from human primary airway epithelial cells.
PF956980 IC50 (μM) PF1367550 IC50 (nM)
Chemokine IFNγ IFNγ+TNFα IFNγ IFNγ+TNFα
CXCL9 0.68 ± 0.12 0.52 ± 0.17 8.4 ± 1.3 17.6 ± 3.0
CXCL10 0.96 ± 0.19 2.12 ± 0.24 10.4 ± 1.7 24.3 ± 2.4
CXCL11 0.76 ± 0.12 1.58 ± 0.33 7.0 ± 0.9 14.5 ± 2.4
Human primary airway epithelial cells were pre-treated for 1h in the presence of either PF956980 or PF1367550 prior to stimulation for 20h in the absence
or presence of IFNγ (10ng/ml) or IFNγ+TNFα (10ng/ml). After this time, media was harvested and the concentrations of CXCL9, CXCL10 and CXCL11
measured by ELISA. Data are presented as mean±SEM, n = 13.
doi:10.1371/journal.pone.0128757.t005
Fig 4. Effect of JAK inhibitors, PF956980 and PF1367550 on IFNγ and IFNγ + TNFα-stimulated phosphorylation of STAT-1 in BEAS-2B cells. BEAS-
2B cells were pre-treated for 1h with either PF956980 or PF1367550 followed by stimulation for 10 min with IFNγ (10ng/ml) () or IFNγ + TNFα (●). Cells were
harvested and western blots performed for phosphorylated STAT-1 and total STAT-1 and quantified by densitometry. Data are representative of n = 4
independent experiments (panels a and c) and presented as mean±SEM, n = 4 (panels b and d).
doi:10.1371/journal.pone.0128757.g004
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Discussion
Transgenic mice that over-express IFNγ exhibit many of the emphysematous changes observed
in COPD [28], thus suggesting that IFNγ is an important molecule driving the development
Fig 5. Effect of JAK inhibitors, PF956980 and PF1367550 on IFNγ and IFNγ + TNFα-stimulated phosphorylation of STAT-1 in human primary airway
epithelial cells.Human primary airway epithelial cells were pre-treated for 1h with either 1μMPF956980 (PF956) or 1μMPF1367550 (PF136) followed by
stimulation for 10 min with either IFNγ (10ng/ml) or IFNγ + TNFα. Cells were harvested and western blots performed for phosphorylated STAT-1 and total
STAT-1 and quantified by densitometry. Data are representative of n = 4 independent experiments (panel a) and presented as mean ± SEM, n = 4 (panel b).
doi:10.1371/journal.pone.0128757.g005
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and continuing pathophysiology of this disease. IFNγ is produced by CD8+ T lymphocytes and
these cells specifically accumulate in the lungs of patients with COPD at the sites of small air-
ways disease [3, 29] and are associated with increased expression of the chemokine receptor,
CXCR3 [2]. This suggests that recruitment of these cells is via CXCR3 and that attenuation of
recruitment of CD8+ cells into the airways of these patients could provide an anti-inflammato-
ry treatment for this glucocorticosteroid-insensitive disease. Since the chemokines that bind to
and activate CXCR3 are induced by IFNγ, the present study investigated the effect of inhibiting
IFNγ signalling in airway epithelial cells using, for the first time in these cells, selective JAK in-
hibitors and demonstrated reductions in CXCR3 chemokine release. In addition, the synergis-
tic action of TNFα with IFNγ to increase expression and release of CXCR3 chemokines has
been reported previously [14, 15, 21] and since TNFα is also elevated in the airways of patients
with COPD [22], the effects of JAK inhibition on this stimulus was also evaluated and showed
similar attenuation of chemokine output. These data would suggest that JAK inhibition could
lead to a reduction in the accumulation of CD8+ lymphocytes in COPD, however other che-
mokines and receptors, possibly CCR5 which is also expressed on these cells [3, 30] could pro-
vide an alternative avenue for cell migration and activation. It is of note that in diseases such as
COPD, increased levels of proteases including neutrophil elastase and matrix metaloprotei-
nases (MMP) such as MMP-2 and MMP-9 [31, 32], could contribute to chemokine processing.
There is evidence that CXCL9, CXCL10 and CXCL11 can all be modified in this way leading to
possible alterations in function [33].
PF956980 has been shown to be a selective inhibitor of JAK activation, most prominently
against JAK2 and JAK3 with no effect on ~30 other kinase pathways including AKT, GSK3β,
IKKβ, IKKi, MAPK1, MAPKAP-K2, MASK, MET, and ROCK1 but with modest effects against
PKA and Lck at concentrations>5μM [24]. In the present study, this compound completely
Fig 6. Effect of JAK inhibitors, PF956980 and PF1367550 on IFNγ and IFNγ + TNFα-stimulated DNA binding of STAT-1 and STAT-3 in BEAS-2B
cells. BEAS-2B cells were pre-treated with either PF956980 (PF956) or PF1367550 (PF136) for 1h followed by stimulation with IFNγ (10ng/ml) or IFNγ
+ TNFα. After 1 h, nuclear extracts of the cells were prepared and TransAM assays for STAT-1 (panel a) and STAT-3 (panel b) were performed. Data are
presented as fold change from baseline ± SEM; n = 4.
doi:10.1371/journal.pone.0128757.g006
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attenuated IFNγ-stimulated release of CXCL9, CXCL10 and CXCL11. The IC50 reported for
PF956980 against JAK3 is ~4nM [24], however this compound has been reported to be effec-
tive against IL-4-induced cytotoxic resistance in chronic lymphocytic leukaemia cells at con-
centrations of ~0.3μM [34] in agreement with the potency of PF956980 in the present study.
Moreover a second, structurally dissimilar molecule, PF1367550 had a similar profile of activity
to PF956980, suggesting that this is not a chemotype-dependent profile, but a function of JAK
enzyme inhibition. However, PF1367550 is a more potent molecule in these assays.
Fig 7. Effect of JAK inhibitors, PF956980 and PF1367550 on IFNγ and IFNγ + TNFα-stimulated expression ofCXCL9,CXCL10, andCXCL11. BEAS-
2B cells were pre-treated with either PF956980 (checked bars), PF1367550 (hashed bars) or dexamethasone (10-6M white bar) for 1h followed by
stimulation with IFNγ (10ng/ml) or IFNγ + TNFα for 6 h. Gene expression of CXCL9 (panels a and b), CXCL10 (panels c and d) andCXCL11 (panels e and f)
were quantified by Taqman RT-PCR. Data are presented as fold change form stimulus ± SEM; n = 3 where 1 indicates the level of mRNA induced by IFNγ or
IFNγ + TNFα in the absence of inhibitors.
doi:10.1371/journal.pone.0128757.g007
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Of note, the human airway epithelial cell line, BEAS-2B responded to both stimuli and in-
hibitors in a similar manner to isolated human primary airway epithelial cells, thus confirming
our previous work and that of others that BEAS-2B are a good model for primary cells in this
system [14, 15]. The inhibitory effects of both JAK-STAT inhibitors were also observed when
TNFα was included with IFNγ to stimulate release of CXCL9, CXCL10, and CXCL11. The syn-
ergistic effect of these cytokines to generate CXCL9, CXCL10 and CXCL11 has been reported
previously [14, 21] and is thought to be mediated via the action of not only STAT-1 but also
NF-κB and CREB [21]. However, inhibition of the JAK pathway continued to inhibit expres-
sion and production of CXCL9, CXCL10 and CXCL11 in the presence of TNFα, indicating
that inhibition of STAT-1 phosphorylation is an essential regulatory step in this process and in-
dicates that JAK inhibition may be a good therapeutic approach in COPD where multiple in-
flammatory mediators interact.
Although IFNγ classically signals through STAT-1 homodimers [35], expression of
CXCL11 has also been reported to occur via STAT-3 [36]. The present study was unable to
measure a significant increase in STAT-3 DNA binding in response to IFNγ stimulation, in
contrast to STAT-1. However, basal DNA binding of STAT-3 was attenuated by both JAK in-
hibitors. STAT-3 is activated during transformation of cells [37] and since BEAS-2B are a
transformed cell line [38], STAT-3 is most likely to be activated basally and can then be inhib-
ited by the JAK inhibitors. Nevertheless, DNA binding of STAT3 increased significantly fol-
lowing stimulation of BEAS-2B cells with the combination of IFNγ and TNFα and again could
be suppressed by JAK inhibition. This suppression of STAT signalling by the JAK inhibitors
used in this study led to inhibition of gene transcription with again PF1367550 being more ef-
fective than PF956980. Taken together, these data indicate that suppression of JAK activation
by selective, small molecule inhibitors, such as PF1367550, would be of benefit in inflammatory
diseases where recruitment of cells via CXCL9, CXCL10 and CXCL11 is important. Currently,
pan-JAK inhibitors are undergoing clinical trials in inflammatory diseases including psoriasis
and rheumatoid arthritis [39, 40] with Tofacitinib, which is structurally similar to PF956980
[24] already approved for use in rheumatoid arthritis in the USA. As such, a similar approach
could be promising in diseases such as COPD where glucocorticosteroids are not effective.
Supporting Information
S1 Fig. Effect of JAK inhibitors, PF956980 and PF136550 and dexamethasone on IFNγ and
IFNγ + TNFα-stimulated release of CXCL9, CXCL10 and CXCL11 from BEAS-2B cells
when added concomitantly. BEAS-2B cells were incubated for with either PF956980 (),
PF1367550 (●), or dexamethasone (▲) and stimulated for 20h with IFNγ (10ng/ml) (panels a-
c) or IFNγ + TNFα (10ng/ml) (panels d-f). Media was harvested and the concentrations of
CXCL9 (panels a and d), CXCL10 (panels b and e) and CXCL11 (panels c and f) were mea-
sured by ELISA. Data are presented as mean±SEM, n = 7–8.
(EPS)
S2 Fig. Effect of JAK inhibitors, PF956980 and PF1367550 and dexamethasone on IFNγ
and IFNγ + TNFα-stimulated release of CXCL9 from human primary airway epithelial cells
derived from non-smokers, smokers and patients with COPD.Human primary airway epithe-
lial cells from non-smokers (panels a and d), smokers (panels b and e) and patients with COPD
(panels c and f) were pre-treated and incubated for 1h with either PF956980 (), PF1367550 (●),
or dexamethasone (▲) followed by stimulation for 20h with either IFNγ (10ng/ml) (panels a-c)
or IFNγ + TNFα (10ng/ml) (panels d-f). Media was harvested and the concentrations of CXCL9
were measured by ELISA. Data are presented as mean±SEM, n = 5–6.
(EPS)
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S3 Fig. Effect of JAK inhibitors, PF956980 and PF1367550 and dexamethasone on IFNγ
and IFNγ + TNFα-stimulated release of CXCL10 from human primary airway epithelial cells
derived from non-smokers, smokers and patients with COPD.Human primary airway epithe-
lial cells from non-smokers (panels a and d), smokers (panels b and e) and patients with COPD
(panels c and f) were pre-treated and incubated for 30 min with either PF956980 (), PF1367550
(●), or dexamethasone (▲) followed by stimulation for 20h with either IFNγ (10ng/ml) (panels
a-c) or IFNγ + TNFα (10ng/ml) (panels d-f). Media was harvested and the concentrations of
CXCL10 were measured by ELISA. Data are presented as mean±SEM, n = 5–6.
(EPS)
S4 Fig. Effect of JAK inhibitors, PF956980 and PF1367550 and dexamethasone on IFNγ
and IFNγ + TNFα-stimulated release of CXCL11 from human primary airway epithelial cells
derived from non-smokers, smokers and patients with COPD.Human primary airway epithe-
lial cells from non-smokers (panels a and d), smokers (panels b and e) and patients with COPD
(panels c and f) were pre-treated and incubated for 30 min with either PF956980 (), PF1367550
(●), or dexamethasone (▲) followed by stimulation for 20h with either IFNγ (10ng/ml) (panels
a-c) or IFNγ + TNFα (10ng/ml) (panels d-f). Media was harvested and the concentrations of
CXCL10 were measured by ELISA. Data are presented as mean±SEM, n = 5–6.
(EPS)
S1 Table. IC50 values for PF956980 and PF1367550 when incubated concomitantly with
IFNγ and IFNγ+TNFα for the release of CXCL9, CXCL10 and CXCL11 from BEAS-2B
cells. BEAS-2B cells were incubated with either PF956980 or PF1367550 for 20h in the absence
or presence of IFNγ (10 ng/ml) or IFNγ+TNFα (10 ng/ml). After this time, media was har-
vested and the concentrations of CXCR3 chemokines measured by ELISA. Data are presented
as mean±SEM, n = 4
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